JP2010531353A - 新規抗凝血組成物、それらを基にした血栓症疾患治療のための医薬組成品、および血液希釈による凝固亢進障害改善のための血漿代用液 - Google Patents

新規抗凝血組成物、それらを基にした血栓症疾患治療のための医薬組成品、および血液希釈による凝固亢進障害改善のための血漿代用液 Download PDF

Info

Publication number
JP2010531353A
JP2010531353A JP2010514672A JP2010514672A JP2010531353A JP 2010531353 A JP2010531353 A JP 2010531353A JP 2010514672 A JP2010514672 A JP 2010514672A JP 2010514672 A JP2010514672 A JP 2010514672A JP 2010531353 A JP2010531353 A JP 2010531353A
Authority
JP
Japan
Prior art keywords
plasma
thrombin
group
hydrogen
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010514672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010531353A5 (enExample
Inventor
イヴァノフナ シナウリゼ、エレナ
イノヤートヴィッチ アタウラークハノフ、ファゾイル
アレクサンドロヴィッチ ブチリン、アンドレイ
ボリソヴィッチ スリモフ、ウラジミール
ニコライヴィッチ ロマノフ、アレクセイ
アレクセーヴィッチ ボゴリューボフ、アレクセイ
ウラジーミロヴィッチ クズネツォフ、ユーリー
ウラジーミロフナ グリブコヴァ、イリーナ
セーギーヴィッチ ゴーバテンコ、アレクサンダー
アナトリーフナ コンダコヴァ、オルガ
Original Assignee
オブシェストヴォ エス オグラニチェノイ オトヴェトストヴェノスチュ “ビオニカ”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オブシェストヴォ エス オグラニチェノイ オトヴェトストヴェノスチュ “ビオニカ” filed Critical オブシェストヴォ エス オグラニチェノイ オトヴェトストヴェノスチュ “ビオニカ”
Publication of JP2010531353A publication Critical patent/JP2010531353A/ja
Publication of JP2010531353A5 publication Critical patent/JP2010531353A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2010514672A 2007-06-28 2008-06-27 新規抗凝血組成物、それらを基にした血栓症疾患治療のための医薬組成品、および血液希釈による凝固亢進障害改善のための血漿代用液 Pending JP2010531353A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2007124202/04A RU2353619C2 (ru) 2007-06-28 2007-06-28 Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции
PCT/RU2008/000401 WO2009002229A2 (en) 2007-06-28 2008-06-27 New anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution

Publications (2)

Publication Number Publication Date
JP2010531353A true JP2010531353A (ja) 2010-09-24
JP2010531353A5 JP2010531353A5 (enExample) 2012-08-23

Family

ID=40186196

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010514672A Pending JP2010531353A (ja) 2007-06-28 2008-06-27 新規抗凝血組成物、それらを基にした血栓症疾患治療のための医薬組成品、および血液希釈による凝固亢進障害改善のための血漿代用液

Country Status (11)

Country Link
US (1) US8426433B2 (enExample)
EP (1) EP2178839A2 (enExample)
JP (1) JP2010531353A (enExample)
KR (1) KR20100028122A (enExample)
CN (1) CN101848894B (enExample)
AU (1) AU2008269258B2 (enExample)
CA (1) CA2692363A1 (enExample)
EA (1) EA020915B1 (enExample)
RU (1) RU2353619C2 (enExample)
UA (1) UA98969C2 (enExample)
WO (1) WO2009002229A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531352A (ja) * 2007-06-28 2010-09-24 オブシェストヴォ エス オグラニチェノイ オトヴェトストヴェノスチュ “ビオニカ” 新規トロンビン機能性化合物およびそれらに基づいた医薬組成物

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2353619C2 (ru) * 2007-06-28 2009-04-27 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции
EA021562B1 (ru) * 2012-08-15 2015-07-30 Общество С Ограниченной Ответственностью "Гематологическая Корпорация" Устройство мониторинга пространственного свертывания крови и ее компонентов
CN116444506A (zh) * 2014-02-07 2023-07-18 艾克赛特赫拉制药有限责任公司 治疗化合物和组合物
RU2685261C1 (ru) * 2018-04-05 2019-04-17 Общество с ограниченной ответственностью "ФК ЛАБОРАТОРИЗ" Вещество 4-амино-1-{ 2-[3-метил-5-(бензолсульфонилокси)фенокси] этил} -пиридиний хлорид, обладающее свойствами биологически активного агента, влияющими на естественно текущие процессы свертываемости крови млекопитающих, антикоагулянт на его основе и способ его получения путем химического синтеза
CN114080382B (zh) * 2019-06-19 2024-05-24 株式会社Lg化学 制备吲哚或吲唑化合物的方法

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3407229A (en) * 1964-09-09 1968-10-22 Baxter Laboratories Inc Phenylcarbamoylethylthiopseudoureas
JPH0341065A (ja) * 1989-07-06 1991-02-21 Morishita Pharmaceut Co Ltd アリールオキシアルキルイソチオウレア臭化水素酸塩類
US5089634A (en) * 1984-08-20 1992-02-18 Georgia Tech Research Corporation Isocoumarins with cationic substituents
JPH05134337A (ja) * 1991-11-08 1993-05-28 Konica Corp ハロゲン化銀写真感光材料
JPH08507503A (ja) * 1993-03-03 1996-08-13 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規４−アミノピリジン、それらの製造方法およびそれらを含有する薬剤
JPH08509723A (ja) * 1993-04-27 1996-10-15 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー アミジノおよびグアニジノ置換ボロン酸トリプシン様酵素阻害剤
JPH10504833A (ja) * 1994-08-30 1998-05-12 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の４−アミノピリダジン、その製造のための方法、及びこれらの化合物を含む薬剤
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
JP2000507588A (ja) * 1996-03-29 2000-06-20 ３―ディメンショナル ファーマシュウティカルズ，インコーポレイテッド プロテアーゼインヒビターとしてのアミジノヒドラゾン
JP2000516203A (ja) * 1996-06-29 2000-12-05 トライジェン・リミテッド トロンビン阻害剤
JP2001500864A (ja) * 1996-09-13 2001-01-23 メルク エンド カンパニー インコーポレーテッド トロンビン阻害物質
JP2005126428A (ja) * 2003-09-30 2005-05-19 Takeda Chem Ind Ltd チアゾリン誘導体およびその用途
US20050159457A1 (en) * 2000-10-06 2005-07-21 Wenxi Pan Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors
WO2005094828A1 (en) * 2004-03-02 2005-10-13 F. Hoffmann-La Roche Ag 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy
JP2009538931A (ja) * 2006-05-31 2009-11-12 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしてのチアゾール化合物およびそれの使用
JP2010531352A (ja) * 2007-06-28 2010-09-24 オブシェストヴォ エス オグラニチェノイ オトヴェトストヴェノスチュ “ビオニカ” 新規トロンビン機能性化合物およびそれらに基づいた医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
US5792769A (en) * 1995-09-29 1998-08-11 3-Dimensional Pharmaceuticals, Inc. Guanidino protease inhibitors
US5792799A (en) * 1996-10-10 1998-08-11 Athena Neurosciences, Inc. Parenteral delivery of MAO A inhibitors
RU2300385C1 (ru) * 2005-12-27 2007-06-10 Елена Ивановна Синауридзе Раствор для коррекции первичных нарушений гемостаза плазмозамещающими растворами нового состава
RU2353619C2 (ru) * 2007-06-28 2009-04-27 Общество С Ограниченной Ответственностью "Бионика" Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3407229A (en) * 1964-09-09 1968-10-22 Baxter Laboratories Inc Phenylcarbamoylethylthiopseudoureas
US5089634A (en) * 1984-08-20 1992-02-18 Georgia Tech Research Corporation Isocoumarins with cationic substituents
JPH0341065A (ja) * 1989-07-06 1991-02-21 Morishita Pharmaceut Co Ltd アリールオキシアルキルイソチオウレア臭化水素酸塩類
JPH05134337A (ja) * 1991-11-08 1993-05-28 Konica Corp ハロゲン化銀写真感光材料
JPH08507503A (ja) * 1993-03-03 1996-08-13 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規４−アミノピリジン、それらの製造方法およびそれらを含有する薬剤
JPH08509723A (ja) * 1993-04-27 1996-10-15 ザ・デュポン・メルク・ファーマシュウティカル・カンパニー アミジノおよびグアニジノ置換ボロン酸トリプシン様酵素阻害剤
JPH10504833A (ja) * 1994-08-30 1998-05-12 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の４−アミノピリダジン、その製造のための方法、及びこれらの化合物を含む薬剤
JP2000507588A (ja) * 1996-03-29 2000-06-20 ３―ディメンショナル ファーマシュウティカルズ，インコーポレイテッド プロテアーゼインヒビターとしてのアミジノヒドラゾン
JP2000516203A (ja) * 1996-06-29 2000-12-05 トライジェン・リミテッド トロンビン阻害剤
JP2001500864A (ja) * 1996-09-13 2001-01-23 メルク エンド カンパニー インコーポレーテッド トロンビン阻害物質
US5886191A (en) * 1997-08-18 1999-03-23 Dupont Pharmaceuticals Company Amidinoindoles, amidinoazoles, and analogs thereof
US20050159457A1 (en) * 2000-10-06 2005-07-21 Wenxi Pan Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl-substituted phenyl acetamides as protease inhibitors
JP2005126428A (ja) * 2003-09-30 2005-05-19 Takeda Chem Ind Ltd チアゾリン誘導体およびその用途
WO2005094828A1 (en) * 2004-03-02 2005-10-13 F. Hoffmann-La Roche Ag 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy
JP2009538931A (ja) * 2006-05-31 2009-11-12 アボット・ラボラトリーズ カンナビノイド受容体リガンドとしてのチアゾール化合物およびそれの使用
JP2010531352A (ja) * 2007-06-28 2010-09-24 オブシェストヴォ エス オグラニチェノイ オトヴェトストヴェノスチュ “ビオニカ” 新規トロンビン機能性化合物およびそれらに基づいた医薬組成物

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ARCHIBALD, JOHN L.; FAIRBROTHER, PAULA; JACKSON, JOHN L.: "Benzamidopiperidines. 3. Carbocyclic derivatives related to indoramin", JOURNAL OF MEDICINAL CHEMISTRY, vol. 17(7), JPN6013029548, 1974, pages 739 - 44, XP002779451, ISSN: 0002558608, DOI: 10.1021/jm00253a017 *
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 8, JPN6014010784, 1998, pages 1697 - 1702, ISSN: 0002767452 *
BRITISH JOURNAL OF PHARMACOLOGY, vol. 114, JPN7013002279, 1995, pages 510 - 516, ISSN: 0002558610 *
CURRENT MEDICINAL CHEMISTRY, vol. 5(4), JPN6014010786, 1998, pages 289 - 304, ISSN: 0002767453 *
FRONTIERS IN BIOSCIENCE, vol. 11(1), JPN6014010791, 2006, pages 113 - 120, ISSN: 0002767456 *
G. B. GUISE: "New approaches to Washfast Dyes for Wool: Isothiuronium salts as protected dye reactive groups", JOURNAL OF THE SOCIETY OF DYERS AND COLOURISTS, vol. 91(7), JPN6013029546, 1975, pages 223 - 228, ISSN: 0002558606 *
JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, JPN6014010789, 2003, pages 3985 - 4001, ISSN: 0002767454 *
JOURNAL OF MOLECULAR MODELING, vol. 13, JPN6014010790, 2007, pages 247 - 254, ISSN: 0002767455 *
NANOSYN COMPOUND LIBRARY, JPN5010010308, 17 April 2007 (2007-04-17), ISSN: 0002558607 *
RAGUSE, BURKHARD; RIDLEY, DAMON D.: "Synthesis and properties of optically active podands incorporating sulfoxide functionality", AUSTRALIAN JOURNAL OF CHEMISTRY, vol. 37(10), JPN6013029545, 1984, pages 2059 - 71, ISSN: 0002558604 *
REGAN B M, JOURNAL OF THE MEDICINAL CHEMISTRY, vol. V10, JPN5010010309, July 1967 (1967-07-01), pages 649 - 652, ISSN: 0002558602 *
SCOZZAFAVA A, EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. V34 N11, JPN5010010304, 1 November 1999 (1999-11-01), FR, pages 939 - 952, ISSN: 0002558605 *
TULECKI, JERZY; KALINOWSKA-TORZ, JADWIGA; MUSIAL, EUGENIUSZ; NACEWICZ-ANJEDANI, HALINA; SENCZUK, LID: "Synthesis of some Bunte salts and isothioureas expected to possess radioprotectant activity. Part X", ANNALES PHARMACEUTICI (POZNAN), vol. 13, JPN7013002276, 1978, pages 139 - 52, ISSN: 0002558603 *
WALKER, GORDON N.; MOORE, MIRIAM ANN; WEAVER, BARBARA N.: "Application of sodium borohydride reduction to synthesis of substituted aminopiperidines, aminopiper", JOURNAL OF ORGANIC CHEMISTRY, vol. 26, JPN6013029549, 1961, pages 2740 - 7, XP002071843, ISSN: 0002558609, DOI: 10.1021/jo01066a030 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010531352A (ja) * 2007-06-28 2010-09-24 オブシェストヴォ エス オグラニチェノイ オトヴェトストヴェノスチュ “ビオニカ” 新規トロンビン機能性化合物およびそれらに基づいた医薬組成物

Also Published As

Publication number Publication date
AU2008269258B2 (en) 2012-12-13
RU2353619C2 (ru) 2009-04-27
AU2008269258A1 (en) 2008-12-31
WO2009002229A3 (en) 2009-03-12
CN101848894B (zh) 2014-08-20
CA2692363A1 (en) 2008-12-31
EA020915B1 (ru) 2015-02-27
RU2007124202A (ru) 2009-01-10
CN101848894A (zh) 2010-09-29
UA98969C2 (ru) 2012-07-10
EA201000064A1 (ru) 2010-06-30
KR20100028122A (ko) 2010-03-11
EP2178839A2 (en) 2010-04-28
WO2009002229A2 (en) 2008-12-31
US20110003826A1 (en) 2011-01-06
US8426433B2 (en) 2013-04-23
AU2008269258A8 (en) 2010-03-25

Similar Documents

Publication Publication Date Title
JP2010531353A (ja) 新規抗凝血組成物、それらを基にした血栓症疾患治療のための医薬組成品、および血液希釈による凝固亢進障害改善のための血漿代用液
CN116262735B (zh) 新型氧代吡啶类化合物及其制备方法和用途
KR20190000898A (ko) 아폽토시스 신호-조절 키나제 억제제
BR102018004862A2 (pt) composto, forma cristalina, composição farmacêutica, e, métodos para inibir ask1 e para tratar uma condição
JP2010531353A5 (enExample)
CN116262724B (zh) 新型氧代吡啶类化合物及其制备方法和用途
KR20150136294A (ko) 인자 ＸＩａ 억제 활성을 가지는 신규한 화합물
CN101282926B (zh) S1p3受体拮抗剂
JP2010531352A5 (enExample)
JP2010531352A (ja) 新規トロンビン機能性化合物およびそれらに基づいた医薬組成物
CN115381827B (zh) 苯骈三氮唑烷基衍生物在制备治疗或预防心血管疾病的药物中的应用
CA2494616A1 (en) Furanthiazole derivatives as heparanase inhibitors
JP6695361B2 (ja) 重水素化チエノピペリジン誘導体、調製方法、及びその使用
WO1998042680A1 (en) Novel anilide compounds and drugs containing the same
JP2006527720A (ja) Ａｌｋ−５受容体の阻害剤としてのチアゾール
CN101486700B (zh) 8-乙酰基色满酮类化合物及其类似物和医药用途
JP7050005B2 (ja) Ｎ－（４，５－ビスメタンスルホニル－２－メチルベンゾイル）グアニジン塩酸塩およびｎ－（４，５－ビスメタンスルホニル－２－メチルベンゾイル）グアニジン塩の結晶変態
CN103613574B (zh) 含有哌嗪结构的2,2-二甲基色满酮类化合物及其类似物的医药用途
TW202140442A (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法
US7718681B2 (en) 5-(1,3-Diaryl-1H-pyrazol-4-ylmethylene)-thiazolidine,2,4-dione derivatives useful as anticancer agent
KR100378091B1 (ko) 항혈전 효과를 나타내는 찰콘 유도체, 그를 포함하는약학적 조성물 및 그의 제조방법
CN103694211B (zh) 2,2-二甲基色满酮类化合物及其类似物的医药用途
CN102924442B (zh) 含有噻唑环的色满类化合物及其类似物和医药用途
KR101118768B1 (ko) 항암제로 유용한5-(3-아릴-1-피리딜-1ｈ-피라졸-4-일메틸렌)-티아졸리딘-2,4-디온 유도체
CN120152950A (zh) 一种烷基羧酸类化合物的晶型及其应用

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110517

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20120704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120704

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140318

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140618

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141118